Dr. Reiman is a principal investigator of the Alzheimer’s Prevention Initiative (API), which includes NIH grants and agreements with Genentech/Roche, Novartis/Amgen, and Avid/Eli Lilly in support of Alzheimer’s disease prevention trials. He is a scientific advisor to Roche and Roche Diagnostics (compensated for travel expenses only), Alkahest, Alzheon, Aural Analytics, Denali, Green Valley, Takeda, United Neuroscience, and Zinfandel. He is also the inventor of a patent held by Banner Health related to the use of biomarkers in Alzheimer’s prevention trials. This editorial was supported by National Institute on Aging grant P30 AG19610 (Eric Reiman, PI).